Will "Robust Pipeline" Yield More New Drugs?
January 21st 2013Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies.
J.P. Morgan: Suits Take San Francisco
January 10th 2013The perennial fat got chewed during the first two days at J.P. Morgan’s annual healthcare conference – buy back stock or raise dividends? – and the usual suspects lurked, but newcomers like Walgreens and not-so-pharma companies like Life Technologies packed the presentation halls and corridors,
SEC Charges Lilly with Corruption Abroad: A Taste of Fines to Come
December 21st 2012The Securities and Exchange Commission filed charges on Eli Lilly and Co. yesterday for violations of the Foreign Corrupt Practices Act (FCPA) that allege the drug maker’s subsidiaries overseas bribed foreign officials in Russia, China, Brazil and Poland.
The Year to Come: EMA's Plans Announced
December 20th 2012At the end of last month, the European Medicines Agency approved its budget and work program for the coming year, promising to implement measures to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking.
Companies Trim Social Media Spending, While Platform Priorities Shift
December 4th 2012Cegedim’s annual industry survey, 2012 US Pharma Insights, reveals that while more pharma companies are using social media and mobile platforms to enhance their sales and marketing initiatives, budgets did not reflect an increase in social media spend.
Pharma's Reputation: A Boost in the US, but China Strikes a Sour Note
November 30th 2012The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre.